Getinge announces date of 2013 Q1 report and conference call

GETINGE will issue its Q1 report for 2013 on Wednesday 17th of April 2013 at 12:00 CET, followed by a conference call at 15:00 CET, hosted by Johan Malmquist, CEO, and Ulf Grunander, CFO.

We invite fund managers, analysts and the media to participate in the conference call. Please see below details to join the conference:

Swedish dial in number: +46 (0) 8 5853 6965
UK dial in number: +44 (0) 20 3478 5300
US dial in number: +1 212 444 0412
Participant passcode: 224195

Agenda
14:45 Call in to the conference
15:00 Review of the Q1 report
15:20 Q&A
16:00 Close of the conference

A recorded version of the conference can be accessed for 5 working days on the following number:
Sweden: +46 (0) 8 5051 3897  
UK: +44 (0) 20 3427 0598
US: +1 347 366 9565
Code: 2241959

During the telephone conference a presentation will be held. To access the presentation, please use this link:

http://www.livemeeting.com/cc/premconfeurope/join?id=2241959&role=attend&pw=pw7034

Alternatively enter the VisionCast site and log into your meeting using the Meeting ID and Password below:

VisionCast: http://www.euvisioncast.com
Your Name: (Enter your name)
Web Meeting ID: 2241959
Web Meeting Password: pw7034

For more information, please contact:

Kornelia Rasmussen
Group Communications
Phone: +46 (0)10 335 5810
E-mail: kornelia.rasmussen@getinge.com

GETINGE GROUP is a leading global provider of products and systems that contribute to quality enhancement and cost efficiency within healthcare and life sciences. We operate under the three brands of ArjoHuntleigh, GETINGE and MAQUET. ArjoHuntleigh focuses on patient mobility and wound management solutions. GETINGE provides solutions for infection control within healthcare and contamination prevention within life sciences. MAQUET specializes in solutions, therapies and products for surgical interventions, interventional cardiology and intensive care.

The information is such that Getinge AB must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act.